In the future, it will be of interest to examine the effect of gemcitabine treatment on MUC4-expressing and non-expressing pancreatic cancer cell lines in vivo to support the pathogenic relevance of MUC4 with the acquisition of resistance to chemotherapeutics. The gene discussed is MUC4; the disease is pancreatic neoplasm.